Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NKT2152-101 trial: what clinicians have said so far
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
- NCT05119335 ↗
- Terminated
- NiKang Therapeutics, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NKT2152-101 (NKT2152 in advanced clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NKT2152-101 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- ccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasms; Recurrent Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Refractory Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Hypoxia; Renal Cell Carcinoma; Hypoxia Inducible Factor (HIF); HIF2α Inhibitor; Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha); Hypoxia Inducible Factor 2α (HIF-2α); Clear Cell
- Interventions
- Oral NKT2152
- Arms
- Phase 1 dose escalation · Experimental
- Phase 2 dose expansion · Experimental
- Enrollment
- 120
- Primary outcomes
- Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 21 days of dosing) in the Dose Escalation Phase (Phase 1)
- Recommended Doses for Expansion (RDEs) Determined in the Dose Escalation Phase (Phase 1)
- Objective Response Rate (ORR) determined by the Investigator in the Dose Expansion Phase (Phase 2)
- Recommended Phase 2 Dose (RP2D)
- Sponsor
- NiKang Therapeutics, Inc.
- Start
- Oct 26, 2021
- Primary completion
- Aug 22, 2025
- Results posted
- No
- Registry record
- NCT05119335 · updated Nov 12, 2025